Last updated: September 24, 2026
Nalmefene hydrochloride is an opioid antagonist with a longer duration of action than naloxone. Its commercial position changed materially after Indivior launched OPVEE, a prescription nalmefene nasal spray, in the United States in 2023. The market remains concentrated, with OPVEE competing against Narcan, Kloxxado and generic naloxone products.
OPVEE has a differentiated pharmacology and long patent runway, but its commercial trajectory depends on emergency-response adoption, payer coverage, public procurement, pricing, and prescriber familiarity. The principal near-term risk is that naloxone remains the established standard for opioid overdose reversal, while the principal long-term opportunity is greater use of longer-acting rescue products in fentanyl-related overdoses.
What is nalmefene hydrochloride and how is it used?
Nalmefene hydrochloride is an opioid receptor antagonist that reverses opioid-induced respiratory depression. It has high affinity for the mu-opioid receptor and a longer elimination half-life than naloxone.
The active ingredient is used in several dosage forms:
| Product or dosage form |
Market status |
Primary sponsor or manufacturer |
Use |
| OPVEE nasal spray |
FDA-approved and marketed |
Indivior PLC |
Emergency treatment of known or suspected opioid overdose |
| Nalmefene injection, Revex |
Previously FDA-approved; U.S. commercial availability ended |
Ohmeda, later associated with Roche/Genentech commercialization |
Opioid overdose reversal |
| Injectable nalmefene products outside the U.S. |
Country-specific availability |
Multiple manufacturers |
Hospital and emergency use |
| Oral nalmefene products |
Marketed in some jurisdictions for alcohol dependence |
Various companies |
Alcohol-use disorder treatment, depending on country |
OPVEE contains nalmefene hydrochloride equivalent to 2.7 milligrams of nalmefene per nasal spray. The product is administered as a single intranasal dose and may be repeated if the patient does not respond or relapses into respiratory depression. The FDA approved OPVEE on May 22, 2023, for emergency treatment of known or suspected opioid overdose in adults and pediatric patients aged 12 years and older. [1]
The product is intended for immediate administration when opioid overdose is suspected. It does not replace emergency medical care.
How does nalmefene compare with naloxone?
Nalmefene’s principal commercial differentiator is duration of action. Nalmefene has a longer half-life than naloxone, creating the potential for more sustained opioid antagonism after exposure to long-acting opioids or potent synthetic opioids.
| Attribute |
Nalmefene hydrochloride |
Naloxone hydrochloride |
| Primary marketed U.S. nasal product |
OPVEE |
Narcan, Kloxxado and generic products |
| U.S. nasal approval |
2023 |
Narcan approved 2015; additional products later |
| Duration of pharmacologic activity |
Longer than naloxone |
Shorter, often requiring repeat dosing |
| Established public-health use |
Limited commercial history in overdose reversal |
Standard of care for decades |
| Generic competition |
Limited for OPVEE nasal formulation |
Extensive and expanding |
| Key clinical argument |
Potentially more durable reversal |
Familiarity, availability and lower cost |
| Principal market barrier |
Adoption and payer acceptance |
None comparable; naloxone is entrenched |
Nalmefene does not automatically displace naloxone. Longer opioid antagonism may increase the risk of prolonged withdrawal, agitation or other adverse effects in opioid-dependent patients. FDA labeling therefore emphasizes appropriate clinical monitoring and continued emergency response. [1]
The commercial decision for buyers often depends on the setting. First responders and public-health programs may prioritize low price and established protocols. Hospitals, correctional facilities and emergency-response organizations may place greater value on prolonged activity and the possibility of reducing repeat dosing.
What is the FDA regulatory status of OPVEE?
OPVEE is FDA-approved under the 505(b)(2) pathway. The product received FDA priority review and was approved on May 22, 2023. Its application relied in part on prior knowledge of nalmefene while incorporating product-specific clinical and pharmacology data for the nasal spray. [1]
FDA milestones
| Milestone |
Date |
| Original nalmefene injection approval, Revex |
1995 |
| Opiant development of intranasal nalmefene |
Before 2023 |
| Indivior acquisition of Opiant |
March 2023 |
| OPVEE FDA approval |
May 22, 2023 |
| U.S. commercial launch |
2023 |
| Expected three-year approval exclusivity end |
May 22, 2026 |
Because nalmefene was previously approved as an active moiety, OPVEE did not receive five-year new chemical entity exclusivity. The product received three-year new-drug application exclusivity based on product-specific clinical investigations. The exclusivity period is expected to run through May 22, 2026, subject to FDA regulatory treatment of any subsequent application. [1,2]
What patents protect nalmefene hydrochloride nasal spray?
The core U.S. protection for OPVEE is directed to the intranasal nalmefene formulation and delivery system rather than to the old active ingredient itself.
| Patent |
Assignee or patent owner |
Subject matter |
Reported expiration |
| U.S. Patent No. 11,925,657 |
Indivior or affiliated Opiant entity |
Intranasal nalmefene formulation and delivery |
January 2039 |
| Related continuation and formulation filings |
Indivior/Opiant-related entities |
Nasal delivery, composition and dosing concepts |
Potentially extending into the late 2030s, depending on claim and patent-term calculations |
The Orange Book listing for OPVEE is the central reference for approved-product patent protection. Patent scope, terminal disclaimers, patent-term adjustment and any later-added listings determine the exact timing of an ANDA applicant’s ability to launch. [3]
The active ingredient itself has limited composition-of-matter value in the United States because nalmefene was known and previously approved. The stronger commercial protection is therefore formulation and delivery IP.
What formulations are protected by nalmefene patents?
The relevant formulation claims may cover:
- Nalmefene hydrochloride in an intranasal aqueous composition.
- Concentration and dose ranges suitable for overdose reversal.
- Excipients that maintain stability and nasal absorption.
- Device configuration and metered-dose delivery.
- Intranasal administration of nalmefene for opioid overdose.
A generic company could attempt to design around individual formulation or device claims. That does not eliminate litigation risk because a competing product may still infringe composition, dosing or delivery claims under different claim sets.
When does nalmefene lose exclusivity?
OPVEE’s regulatory exclusivity is expected to end in May 2026, while its principal listed patent protection is expected to continue into 2039.
| Protection type |
Expected timing |
Commercial effect |
| FDA three-year exclusivity |
May 22, 2026 |
Limits approval of certain competing applications relying on OPVEE-specific investigations |
| Orange Book formulation or device patent |
January 2039 or later for applicable claims |
Creates a major barrier to U.S. generic launch |
| Trade secrets and manufacturing know-how |
Indefinite if maintained |
May complicate replication but does not independently block approval |
| Trademark protection for OPVEE |
Renewably maintainable |
Protects branding, not the active ingredient |
The 2026 exclusivity expiry does not necessarily create immediate generic entry. An ANDA applicant must address listed patents, typically through paragraph III certification, paragraph IV certification or a statement that the patent is not applicable. A paragraph IV challenge can trigger patent litigation and a 30-month stay of FDA approval if the sponsor sues within the statutory period. [4]
What is the Orange Book status of OPVEE?
OPVEE is listed in the FDA Orange Book as a prescription product with associated patent information. The commercial importance of the listing is greater than the three-year regulatory exclusivity because it gives Indivior a potential basis to delay or prevent approval of a competing generic nasal spray until patent expiry or successful invalidity or noninfringement litigation.
Paragraph IV challenge and generic entry scenarios
No publicly established paragraph IV settlement or final court judgment has displaced the principal OPVEE patent protection. The main entry scenarios are:
- A generic applicant waits for patent expiry and files with a paragraph III certification.
- A generic applicant files a paragraph IV certification and challenges validity, enforceability or infringement.
- A rival develops a materially different nasal device or formulation that avoids the listed claims.
- A competing nalmefene product reaches the market through a separate regulatory pathway rather than an ANDA.
The most credible U.S. generic-entry window is therefore patent-dependent, not simply tied to the May 2026 exclusivity date.
Which companies are challenging nalmefene hydrochloride?
The competitive field includes manufacturers of naloxone rather than confirmed direct challengers to OPVEE.
| Company |
Product or position |
Competitive relevance |
| Indivior |
OPVEE nalmefene nasal spray |
Originator and principal U.S. commercial sponsor |
| Emergent BioSolutions |
Narcan naloxone nasal spray |
Established branded competitor |
| Hikma Pharmaceuticals |
Naloxone injection and related products |
Hospital and generic competition |
| Teva Pharmaceuticals |
Generic naloxone products |
Price pressure and broad distribution |
| Sandoz and other generic manufacturers |
Naloxone dosage forms |
Institutional and pharmacy competition |
| Public-health agencies and nonprofit suppliers |
Naloxone distribution programs |
Demand creation and substitution pressure |
The competitive threat is not limited to approved drugs. Public procurement programs, state standing orders, over-the-counter naloxone access and nonprofit distribution can shift overdose-reversal demand toward naloxone even when nalmefene has a pharmacologic advantage.
How strong is the nalmefene patent estate?
The patent estate is moderately strong for the specific OPVEE product but weaker at the molecule level.
Strengths
- The core active ingredient is embedded in a nasal formulation with patent protection extending well beyond the 2026 regulatory exclusivity date.
- OPVEE’s delivery system creates potential infringement issues for closely similar products.
- A generic company may need to develop both a noninfringing formulation and a distinct nasal device.
- Indivior acquired Opiant partly to obtain overdose-reversal assets and associated intellectual property. [5]
Weaknesses
- Nalmefene is an old, previously approved active ingredient.
- Patent challenges can target obviousness, written description, enablement and claim construction.
- A competitor could pursue a different dose, excipient profile or device.
- Naloxone products remain clinically and commercially substitutable in many procurement settings.
- Long patent life does not guarantee premium pricing or broad formulary access.
The estate is strongest against a close copy of OPVEE and weaker against a product that uses nalmefene in a substantially different delivery system.
What licensing deals and acquisitions involve nalmefene?
Indivior acquired Opiant Pharmaceuticals in 2023 in a transaction valued at approximately $145 million in upfront consideration, with additional contingent value potentially payable under the transaction terms. Opiant had developed intranasal nalmefene for opioid overdose. [5]
The transaction gave Indivior control of:
- OPVEE and its FDA application.
- Opiant’s nalmefene formulation and delivery technology.
- Related patents and regulatory assets.
- A commercial entry point in overdose rescue products outside Indivior’s traditional opioid-dependence treatment franchise.
The acquisition reduced Indivior’s dependence on Sublocade and Suboxone-related products by adding a product tied to the broader opioid-overdose response market.
What is the financial trajectory for nalmefene hydrochloride?
OPVEE launched late in 2023, so its financial contribution has been limited relative to Indivior’s established products. Indivior reports OPVEE within its broader product portfolio, and public disclosures do not consistently provide a full standalone revenue history for every reporting period.
The commercial trajectory can be divided into four stages:
| Stage |
Period |
Financial characteristics |
| Prelaunch and acquisition |
2023 |
Acquisition expenditure, regulatory launch costs and limited initial sales |
| Market entry |
2023-2024 |
Early prescription uptake, distributor stocking and payer-access work |
| Institutional expansion |
2025-2027 |
Potential growth through emergency services, hospitals and public agencies |
| Mature market or competitive erosion |
2028 onward |
Outcome depends on reimbursement, procurement and patent challenges |
Indivior’s corporate revenue is primarily driven by Sublocade, Suboxone and other addiction-treatment products. OPVEE is strategically important but remains a smaller revenue contributor than Sublocade. The product’s upside is linked to the size of the opioid-overdose market, while its near-term revenue base is constrained by:
- Naloxone’s lower cost and entrenched use.
- Public-sector purchasing practices.
- Limited long-term prescribing habits for nalmefene.
- Reimbursement variability.
- The need to educate clinicians and first responders.
- Potential payer resistance to a premium rescue product.
A successful institutional strategy could create recurring volume because overdose-reversal products are purchased for emergency stockpiles, ambulances, hospitals, pharmacies, schools, correctional facilities and community programs. A pharmacy-only strategy would likely produce slower adoption because consumers and caregivers already recognize naloxone.
What generic launch risks exist for OPVEE?
Generic launch risk is low before 2026 because of FDA exclusivity and the listed patent estate. Risk increases after the first legally effective paragraph IV filing or patent expiry.
Near-term risks
- A competing nalmefene product using a noninfringing formulation.
- Regulatory approval of a product that does not rely on OPVEE’s clinical investigation package.
- Aggressive naloxone pricing that prevents OPVEE from gaining share.
- Public procurement decisions that favor naloxone despite nalmefene’s longer action.
Medium-term risks
- Paragraph IV litigation against formulation or device patents.
- Patent invalidity findings.
- Settlement agreements granting an authorized generic or delayed entry.
- Payer policies that classify OPVEE as nonpreferred.
- Declining prices in the overdose-reversal category.
Likely launch scenarios
| Scenario |
Timing |
Expected impact |
| No successful challenge |
Through late 2030s |
OPVEE retains formulation-based protection |
| Paragraph IV challenge settled with delayed entry |
Before 2039 |
Limited erosion on agreed date |
| Patent invalidation or noninfringement ruling |
Before 2039 |
Earlier generic or competing-product entry |
| Non-ANDA competing nalmefene product |
Before or after 2026 |
Market share pressure without direct OPVEE generic substitution |
| Naloxone remains dominant |
Ongoing |
Caps OPVEE pricing and volume growth |
What is the geographic coverage of nalmefene hydrochloride IP?
The strongest commercial protection is in the United States because OPVEE is FDA-approved and has an Orange Book listing. International protection depends on national filings, granted patents, patent-term adjustments and regulatory approvals.
The European and other international markets have different rules for:
- Patent listing.
- Regulatory exclusivity.
- Generic and hybrid applications.
- Pediatric extensions.
- Supplementary protection certificates.
- Public-health procurement.
- Emergency overdose-reversal access.
A U.S. patent does not prevent commercial entry in Europe, Canada or other jurisdictions. Indivior’s international opportunity depends on country-specific approvals and reimbursement rather than the U.S. Orange Book alone.
Key Takeaways
- Nalmefene hydrochloride is commercially differentiated by longer opioid-antagonist activity than naloxone.
- Indivior’s OPVEE is the principal U.S. nalmefene overdose product.
- FDA approval occurred on May 22, 2023.
- Three-year regulatory exclusivity is expected to end on May 22, 2026.
- The key OPVEE patent protection is formulation and nasal-delivery based, with reported protection extending into 2039.
- Nalmefene has a stronger product-specific patent position than molecule-level exclusivity.
- Naloxone remains the main commercial competitor because of established use, broad access and lower-cost supply.
- Indivior acquired Opiant Pharmaceuticals for approximately $145 million in upfront consideration, adding OPVEE and related IP.
- OPVEE’s revenue contribution remains small relative to Indivior’s addiction-treatment franchise, but institutional procurement could support growth.
- Generic entry is unlikely to be determined by the 2026 exclusivity expiry alone. Orange Book patents and paragraph IV litigation are more important.
FAQs About Nalmefene Hydrochloride
Is nalmefene hydrochloride the same as naloxone?
No. Both reverse opioid effects, but nalmefene has a longer duration of action. Naloxone has a longer commercial history and broader market penetration.
Is OPVEE available over the counter?
OPVEE is an FDA-approved prescription product. Narcan naloxone nasal spray has received over-the-counter authorization, giving naloxone a distribution advantage in consumer and community settings. [6]
Does nalmefene have orphan-drug exclusivity?
OPVEE’s principal U.S. protection is based on FDA approval exclusivity and patents. It is not generally identified as relying on orphan-drug exclusivity for its opioid-overdose indication.
Can a generic company launch nalmefene after May 2026?
Not necessarily. The end of three-year FDA exclusivity may permit certain applications to proceed, but Orange Book patents can delay approval or trigger paragraph IV litigation.
What is the main investment risk for OPVEE?
The main risk is commercial substitution by naloxone. Even with longer activity, OPVEE must overcome entrenched clinical protocols, lower-priced competitors, public procurement preferences and payer restrictions.
References
- U.S. Food and Drug Administration. (2023). OPVEE (nalmefene hydrochloride) nasal spray prescribing information.
- U.S. Food and Drug Administration. (2023). New drug application approval letter for OPVEE.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Code, 21 U.S.C. § 355(j). (2024). Abbreviated applications for new drugs and patent certifications.
- Indivior PLC. (2023). Indivior completes acquisition of Opiant Pharmaceuticals.
- U.S. Food and Drug Administration. (2023). FDA approves first over-the-counter naloxone nasal spray.
